<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Katreddy RR</submitter><funding>NIA NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>5</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5833766</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(1)</volume><pubmed_abstract>The oncogenic epidermal growth factor receptor (EGFR) is commonly overexpressed in solid cancers. The tyrosine kinase activity of EGFR has been a major therapeutic target for cancer; however, the efficacy of EGFR tyrosine kinase inhibitors to treat cancers has been challenged by innate and acquired resistance at the clinic. Accumulating evidence suggests that EGFR possesses kinase-independent pro-survival functions, and that cancer cells are more vulnerable to reduction of EGFR protein than to inhibition of its kinase activity. The molecular mechanism underlying loss-of-EGFR-induced cell death remains largely unknown. In this study, we show that, unlike inhibiting EGFR kinase activity that is known to induce pro-survival non-selective autophagy, downregulating EGFR protein, either by siRNA</pubmed_abstract><journal>Oncogenesis</journal><pubmed_title>Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt.</pubmed_title><pmcid>PMC5833766</pmcid><funding_grant_id>R21 AG045382</funding_grant_id><funding_grant_id>R01 CA203737</funding_grant_id><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Huang G</pubmed_authors><pubmed_authors>Wu B</pubmed_authors><pubmed_authors>Bollu LR</pubmed_authors><pubmed_authors>Weihua Z</pubmed_authors><pubmed_authors>Dai Y</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors><pubmed_authors>Su F</pubmed_authors><pubmed_authors>Rea MA</pubmed_authors><pubmed_authors>Srivastava S</pubmed_authors><pubmed_authors>Xian N</pubmed_authors><pubmed_authors>Thomas R</pubmed_authors><pubmed_authors>Briggs JM</pubmed_authors><pubmed_authors>Katreddy RR</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt.</name><description>The oncogenic epidermal growth factor receptor (EGFR) is commonly overexpressed in solid cancers. The tyrosine kinase activity of EGFR has been a major therapeutic target for cancer; however, the efficacy of EGFR tyrosine kinase inhibitors to treat cancers has been challenged by innate and acquired resistance at the clinic. Accumulating evidence suggests that EGFR possesses kinase-independent pro-survival functions, and that cancer cells are more vulnerable to reduction of EGFR protein than to inhibition of its kinase activity. The molecular mechanism underlying loss-of-EGFR-induced cell death remains largely unknown. In this study, we show that, unlike inhibiting EGFR kinase activity that is known to induce pro-survival non-selective autophagy, downregulating EGFR protein, either by siRNA</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Jan</publication><modification>2026-05-05T03:52:22.257Z</modification><creation>2026-04-07T21:21:13.537Z</creation></dates><accession>S-EPMC5833766</accession><cross_references><pubmed>29358623</pubmed><doi>10.1038/s41389-017-0021-7</doi></cross_references></HashMap>